A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma.
Wang D, Fu H, Que Y, Ruan H, Xu M, Long X, Yu Q, Li C, Li Z, Cai S, Chen W, Sun C, Hu G, Wang S, He D, Mei J, Wang W, Li C.
Wang D, et al. Among authors: yu q.
J Transl Med. 2023 Nov 15;21(1):812. doi: 10.1186/s12967-023-04655-w.
J Transl Med. 2023.
PMID: 37964302
Free PMC article.